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doi:10.1016/j.jmii.2011.04.014Background: The aim of this study was to review the risk factors and clinical, bacteriological,
and epidemiological characteristics of Stenotrophomonas maltophilia infections in our
neonatal intensive care unit.
Methods: A retrospective matched caseecontrol study was performed by comparing 23
cases of S maltophilia with 45 controls to identify the potential risk factors. To identify
the case patients, the admission and medical records of patients in the neonatal intensive
care unit and records from the Microbiology Department were reviewed between 2003 and
2008.
Results: Sepsis in two neonates (9%), conjunctivitis in two neonates (9%), and ventilator-
associated pneumonia in 19 (82%) neonates were determined. Invasive-procedures, expo-
sure to aminoglycoside and carbapenem, total parenteral nutrition, histamine 2 blockers,
exposure to steroids, cholestasis, and duration of hospitalization were significantly associ-
ated with S maltophilia infections (p< 0.05). On multivariate analysis, invasive procedures
(odds ratio, 18.81) and duration of hospitalization (odds ratio, 1.06) were determined to be
the risk factors for S maltophilia infection. The most active antimicrobial agent was
trimethoprim/sulfamethoxazole (87%) for S maltophilia infection, and the mortality rate
was 17%.
Conclusions: Neonatologists should avoid from unnecessary invasive procedures and broad-
spectrum antibiotics to reduce S maltophilia infections. Invasive procedures should be
finished in the shortest time possible. Agent/factor-specific antibacterial treatment should
be administered. Patients being discharged as early as possible will also reduce infectionof Neonatology, Karadeniz Technical University, Kalkınma Mah. Farabi Hastanesi, 61080 Trabzon,
@hotmail.com (M. Mutlu).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
468 M. Mutlu et al.frequency. Stenotrophomonas maltophilia should be considered in patients with high Steno-
trophomonas infection risk factors.
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Stenotrophomonas maltophilia is a multidrug-resistant, non-
fermenting, aerobic, gram-negative bacillus that is generally
regarded an as opportunistic pathogen. It is an important
nosocomial pathogen observed with increasing frequency.1e3
Stenotrophomonas maltophilia causes hospital-acquired
infections, such as pneumonia, bacteremia, endocarditis,
and central nervous system, ophthalmological, urinary tract,
bone and joint, skin and soft tissue, and gastrointestinal
infections, and is occasionally associated with septic shock in
critically ill and immunosuppressed patients.1e3 Most of the
clinical studies dealing with S maltophilia have focused on
the adult population, and only a few studies have examined
the risk factors for S maltophilia in newborns and children.3e5
Theaimof this studywas to reviewthe risk factors andclinical,
bacteriological, and epidemiological characteristics of S mal-
tophilia infections in our neonatal intensive care unit (NICU)
between January 2003 and August 2008.
Materials and methods
Patient and control identification
This retrospective matched caseecontrol study was carried
out in neonates with S maltophilia infections at the Kar-
adeniz Technical University NICU between 2003 and 2008. To
identify the case patients, we reviewed the admission and
medical records of patients in the NICU and records from the
Microbiology Department in the study period. Control
patients were selected from the patients who stayed in the
NICU for at least 72 hours and had neonatal pneumonia
and/or nosocomial sepsis caused by pathogens other than S
maltophilia. To determine the risk factors for S maltophilia
infections among neonates, 23 case patients were compared
with 45 control patients. Medical charts of all infants with
positive cultures for S maltophilia and control cases were
reviewed for birth weight; gestational age; delivery type;
postnatal age at hospitalization; prolonged rupture of
membranes; invasive procedures (mechanical ventilation,
intubation, urinary catheter, umbilical catheter); duration
of mechanical ventilation (day); exposure to antimicrobial
agents (aminoglycosides, carbapenems, cephalosporins,
penicillins); administration of total parenteral nutrition
(TPN); duration of TPN; histamine 2 (H2) blockers; exposure
to steroids; cholestasis; elevated liver enzymes; death;
sepsis-related death; and duration of hospitalization. All the
risk factors for infection were calculated before the onset of
infection in both groups.
Definitions
Sepsis was considered in the presence of two or more of the
following criteria associated with positive blood culture: (1)fever or hypothermia, (2) tachycardia, (3) tachypnea or
hyperventilation, and (4) abnormal white blood cells or an
increase in immature forms. Septic shock was defined as
refractory hypotension despite adequate fluid resuscitation
and cardiac output.6 Ventilator-associated pneumonia (VAP)
was defined as an infection in a newborn requiring at least 48
hours of mechanical ventilation and developing new and
persistent radiographic evidence of focal infiltrates 48 hours
or more after the initiation of mechanical ventilation.7
Conjunctivitis was defined as the presence of a purulent
ocular discharge, erythema, and edema of the lids.
Preterm labor was defined as onset labor before 37
weeks’ gestation. Prolonged rupture of membranes was
defined as rupture of membranes 18 hours or more before
delivery. Cholestasis was defined as direct bilirubin level
greater than 2 mg/dL. Hypoalbuminemia was taken as
a serum albumin level lower than 3 g/dL. Death was
regarded as S maltophilia related if it occurred within 7
days of the positive culture and if clinical signs and symp-
toms of the infections were documented in the medical
record when the patient died.
The presence of an umbilical venous catheter was
included as a risk factor only if inserted before the onset of
infection and in place at the time of a positive culture
result. Surgery was included only if the procedure was per-
formed 7 days or less before the onset of infection. Urinary
catheter, TPN, and H2 blockers were accepted as a risk
factor only if these parameters were applied to patients
within one week before the isolation of S maltophilia.
Cholestasis and elevated liver enzymes were accepted as
risk factors, only if they are present at the time a positive
culture was obtained. Previous antimicrobial (penicillin,
aminoglycoside, cephalosporin, and carbapenem) and
steroid therapies were recorded within 2 weeks before the
isolation of S maltophilia.
Microbiology
Stenotrophomonas maltophilia isolates were identified
using conventional tests and the Phoenix Automated
Microbiology System (Becton Dickinson Diagnostic Systems,
Sparks, Maryland, USA). Antimicrobial susceptibility tests
were performed using Phoenix GN Combo Panels (Becton
Dickinson Diagnostic Systems) (combined identification and
susceptibility cards) and interpreted as described by the
Clinical and Laboratory Standards Institute.8 The following
antimicrobials were tested: ceftazidime, chloramphenicol,
levofloxacin, and trimethoprim/sulfamethoxazole.
Statistical analysis
Descriptive statistics was used for all the studied variables.
Conformity of the data obtained in measurements to normal
distribution was analyzed using the KolmogoroveSmirnov
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analyzed using Student t test, and those not conforming to
normal distribution were analyzed using the ManneWhitney
U test. Data obtained by measurement are given as mean -
 standard deviation. Data obtained by counting are pre-
sented as numbers (%); analyses were done using the Chi-
square test. Statically significant parameters were included
to multivariate logistic regression model in univariate anal-
yses. Results of the analysis are presented as p values, odds
ratios (ORs), and 95% confidence intervals (CIs). A p value
less than 0.05 was regarded as statistically significant.
Results
Stenotrophomonas maltophilia was isolated in 46 clinical
samples between January 2003 and August 2008. It was
isolated from tracheal aspiration in 41 (90%) samples,
purulent ocular discharge in two (4%) samples, blood in two
(4%) samples, and urine in one (2%) sample. Twenty-three
samples (50%) were excluded because these patients had
no infection criteria and these samples were accepted as
colonization. A total of 23 samples from different patients
were accepted to be associated with S maltophilia infec-
tions. The demographic characteristics of the patients with S
maltophilia infection and the control group are shown in
Table 1. Of the 23 patients with S maltophilia infections, 11
(48%) were females and 12 (52%) were males, with mean
birth weight, gestational age, and postnatal age of
2,176 928 g, 33.9 4.5 weeks, and 6.4 8.0 days,
respectively. Stenotrophomonas maltophilia infections were
more frequently observed in newborns with a birth weight
less than 2,500 g and gestational age less than 37 weeks.
Two neonates (9%) had positive blood culture for S
maltophilia. Stenotrophomonas maltophilia was isolated
from purulent ocular discharge in two neonates (9%) and
tracheal aspiration culture in 19 (82%) neonates. All
neonates fulfilled the definitions of sepsis, conjunctivitis,
and VAP. There was no polymicrobial infection in these 23Table 1 Characteristics of cases of S maltophilia and control g
Characteristic S maltophilia (n
Birth weight (g) 2,176 928
2,500 10 (43)
2,499 13 (57)
Gestational age (wk) 33.9 4.5
37 8 (35)
366/7 15 (65)
Delivery type
Vaginal 9 (39)
Caesarean 14 (61)
Sex
Female 11 (48)
Male 12 (52)
Postnatal age at hospitalization (d) 6.4 8.0
Prolonged rupture of membranes 1 (4)
Data are presented as n (%) or mean standard deviation.
366/7Z 36 weeks plus 6 days; S maltophiliaZ Stenotrophomonas mapatients. The most active antimicrobial agents were
trimethoprim/sulfamethoxazole (87%), levofloxacin (76%),
and chloramphenicol (63%). Trimethoprim/sulfamethox-
azole (TMPeSMZ) was used in 18 patients, levofloxacin was
used in three patients, and ciprofloxacin eye drop was used
in two neonates with conjunctivitis. Sixty-seven percent
(nZ 30) of the control patients had neonatal pneumonia,
and the others had nosocomial sepsis caused by pathogens
other than S maltophilia.
Invasive-procedure (including mechanical ventilation,
intubation, and urinary catheter) exposure to aminoglyco-
side and carbapenem, TPN, H2 blockers, exposure to
steroids, cholestasis, and duration of hospitalization were
significantly associated with S maltophilia infections (Table
2). Durations of mechanical ventilation, urinary catheter,
and TPN were statistically significantly longer in newborns
associated with S maltophilia infections than in those in
controls (Table 2). Four neonates with S maltophilia
infectionsdone of them with sepsis and the others with
VAPddied during the study period. The mortality rate for S
maltophilia infections was 17%. The mortality rate was
statistically significantly higher in newborns with S malto-
philia infections than that in the controls (pZ 0.011).
On multivariate analysis, invasive procedures (OR,
18.81; 95% CI, 1.9e184.6; pZ 0.012) and duration of
hospitalization (OR, 1.06; 95% CI, 1.004e1.133; pZ 0.037)
were determined to be the risk factors for S maltophilia
infection (Table 3).
Discussion
This is the first study to investigate the predisposing factors
and clinical characteristics of S maltophilia infections in the
neonatal period. Stenotrophomonas maltophilia infections
are an important cause of life-threatening nosocomial
infections in children.3 Because S maltophilia is resistant to
empirical antibiotics (such as cefotaxime, ampicillin,
gentamicin, etc.) used in neonatal infections. Increasingroup
Z 23) Control group (nZ 45) p
2,537 823 0.124
27 (60) 0.195
18 (40) 0.255
35.2 3.7 0.058
26 (58) 0.072
19 (42)
27 (60) 0.128
18 (40)
20 (44) 0.803
25 (56)
4.7 5.2 0.890
4 (9) 0.656
ltophilia.
Table 2 Risk factors of Stenotrophomonas maltophilia infections
Characteristic S maltophilia (nZ 23) Control group (nZ 45) p
Invasive procedures 21 (91) 13 (29) 0.001
Mechanical ventilation 21 (91) 6 (13) 0.001
Duration of mechanical ventilation (d) 13.5 20.7 0.7 1.8 0.001
Urinary catheter 12 (52) 4 (9) 0.001
Duration of urinary catheter (d) 4.1 6.4 0.2 0.7 0.001
Umbilical catheter 6 (26) 8 (18) 0.529
Duration of umbilical catheter (d) 1.2 2.2 0.7 2.0 0.409
Exposure to antimicrobial agent 23 (100) 27 (60) 0.001
Penicillin 7 (30) 26 (58) 0.060
Aminoglycoside 19 (83) 23 (51) 0.012
Cephalosporin 1 (4) 5 (11) 0.656
Carbapenem 18 (78) 14 (31) 0.001
TPN 20 (87) 12 (27) 0.001
Duration of TPN (d) 15.5 20.9 4 10.5 0.001
Histamine 2 blockers 21 (91) 10 (22) 0.001
Corticosteroid therapy 7 (30) 0 (0) 0.001
Cholestasis 6 (26) 1 (2) 0.005
Elevated liver enzymes 2 (9) 3 (7) 0.554
Low serum albumin level 6 (26) 9 (20) 0.792
Duration of hospitalization (d) 50.8 44 10.8 11.7 0.001
Data are presented as n (%) or mean standard deviation.
TPNZ total parenteral nutrition.
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very low birth weights and prolonged hospitalization, has
increased the observance of nosocomial S maltophilia
infection rates in newborns. Stenotrophomonas maltophilia
causes nosocomial pneumonia, bacteremia, central nervous
system infections, endocarditis, and ophthalmological,
urinary tract, bone and joint, skin and soft tissue, and
gastrointestinal infections.1,9 The respiratory tract is the
most common site of S maltophilia infections.10,11 In our
study, 82% of the S maltophilia-related infections were VAP,
9% were sepsis, and 9% were conjunctivitis.
Differentiating colonization from infection is difficult,
especially in cultures obtained from tracheal aspiration.11
Only 19 of 41 (46%) tracheal aspiration samples were
accepted as infected in our study. This finding is in accor-
dance with literature. del Toro et al.11 reported that 49% of
the patients with positive respiratory samples were
accepted to have a respiratory tract infection.
Various risk factors have been reported for infection or
colonization by S maltophilia, including prior antibiotic
therapy; prolonged hospitalization; presence of a central
venous catheter, neutropenia, or cytotoxic chemotherapy;Table 3 Risk factors of Stenotrophomonas maltophilia infectio
Characteristic Odds ratio
Invasive procedures 18.81
Duration of hospitalization 1.06
Gestational age (wk) 1.19
Total parenteral nutrition 0.23
Cholestasis 1.58
Carbapenem 1.01immunosuppressive therapy; prolonged stay in the intensive
care unit; mechanical ventilation or tracheotomy; underlying
disease (hepatobiliary, chronic pulmonary, and cardiovas-
cular diseases; organ transplantation; dialysis; intravenous
drug use; and infection with the human immunodeficiency
virus or malignancy); corticosteroid therapy; exposure to
patients with S maltophilia wound infection; received
parenteral nutrition; and transportation to hospital by
airplane.1,5,11e13
In our study, invasive-procedure (including mechanical
ventilation, intubation, urinary catheter) exposure to ami-
noglycoside and carbapenem, TPN, H2 blockers, exposure
to steroids, cholestasis, and duration of hospitalization
were significantly associated with S maltophilia infections.
Because the study group had a significantly lower gesta-
tional age and low birth weight, they had long-term hospi-
talization and more often had been exposed to invasive
procedures. Nosocomial sepsis is common in these groups.
Nosocomial sepsis further increases hospitalization time
and exposure to invasive procedures. Previous exposure to
broad-spectrum antimicrobial agents, especially carbape-
nem, ampicillin, gentamicin, vancomycin, metronidazole,ns (multivariate analysis)
95% Confidence interval p
1.9e184.6 0.012
1.004e1.133 0.037
0.890e1.605 0.235
0.022e2.342 0.214
0.069e36.121 0.773
0.896e1.132 0.111
S maltophilia infections in neonates 471piperacillin, cefotaxime, ceftazidime, ciprofloxacin,
tobramycin, and cefepime, is one of the significant risk
factors for the development of S maltophilia colonization
and infection.14e17 Carbapenem and aminoglycosides are
empirically used for nosocomial sepsis in our unit. In our
study, 78% and 83% of the neonates with S maltophilia
infection were exposed to carbapenem and aminoglyco-
sides, respectively, before the onset of S maltophilia
infection. These antibiotics may cause S maltophilia colo-
nization in the respiratory tract. Moreover, S maltophilia
constitutes 3% of hospital-acquired blood stream infections
in our hospital.18 These results indicate that S maltophilia is
a common causative agent in nosocomial infection in our
hospital.
Cholestasis was determined as a significant risk factor in
the development of S maltophilia infection on univariate
analysis and was not an independent risk factor on multi-
variable analysis; we considered that cholestasis was more
related to prolonged hospitalization, parenteral nutrition,
and exposure to invasive procedures, rather than being
a direct predisposing factor for infection.
H2 blockers are frequently used in patients in the NICU
to prevent the development of stress ulcers and bleeding.
They raise intragastric pH, which may enhance the coloni-
zation of the stomach by gram-negative bacteria and
thereby contribute to the development of nosocomial
pneumonia.19 Cook et al.20 reported an increased risk of
pneumonia associated with the use of H2-receptor antag-
onists. We determined a relationship between the use of
H2-receptor antagonists and S maltophilia infection.
Management of S maltophilia-associated infection is
difficult because many strains of S maltophilia display
resistance to multiple antibiotics. It appears that TMPeSMZ;
ticarcillin-clavulanate; and quinolones, such as levofloxacin
or ciprofloxacin, are the most sensitive antibiotics for S
maltophilia-associated infections.3,5,12,21e24 The increasing
resistance to TMPeSMZ represents an important problem for
laboratory staff and clinicians.25 Gales et al.26 reported that
the resistance to TMPeSMZ is increasing. The rate of resis-
tance to TMPeSMZ ranges from 2% in Canada and Latin
America to 10% in Europe. In a previous study in our hospital,
the level of TMPeSMZ resistance was 2.3%,22 and the rise to
13% in our study demonstrates this increasing resistance.
There is a concern over using TMPeSMZ in the neonatal
period. TMPeSMZ competes with bilirubin for binding to
albumin, and it can increase the level of indirect bilirubin.
Hypoalbuminemia contributes to an increase in the level of
indirect bilirubin. Hypoalbuminemia can be observed in the
course of S maltophilia infections. Hypoalbuminemia and
competition of TMPeSMZwith bilirubin for binding to albumin
areapotential risk for hyperbilirubinemia.However, neonatal
hyperbilirubinemia is commonly observed in the first week of
life, and S maltophilia infections usually occur later than the
first week. In our study, 23% of S maltophilia infections
occurred in the first week of life, but no hyperbilirubinemia
was observed. It has been reported that no adverse side
effects, including increased indirect hyperbilirubinemia,
associated with the use of TMPeSMZ, were observed in the
neonatal period.27 In our study, no other adverse side effects
were observed to accompany TMPeSMZ. We, therefore,
recommend TMPeSMZ for antimicrobial therapy of S malto-
philia infection.Lai et al.21 reported that low serum albumin level can be
used as a poor prognostic factor for S maltophilia bacter-
emia. However, we determined no statistically significant
difference in serum albumin levels between cases with S
maltophilia infection and the controls.
The mortality rates associated with S maltophilia
infections ranged from 21% to 40.6% in adult and pediatric
patients.21,23,24,28 Delayed treatment for S maltophilia
increases the mortality rate.29 The mortality rate in our
study (17%) was lower than that in the literature. Early
detection and suitable antimicrobial therapy was effective
in the improved outcome in our patients.
In conclusion, the most important risk factors for S mal-
tophilia infection in neonates are invasive procedures;
previous exposure to antibiotics, such as carbapenem and
aminoglycoside; and prolonged hospitalization. Invasive
procedure is a risk factor for nosocomial infections, such as
S maltophilia, but invasive procedures are required critically
ill neonates. For this reason, hand hygiene is the best method
to prevent nosocomial infections. Broad-spectrum antibiotics
should be avoided as much as possible in NICU patients, and
agent/factor-specific antibacterial treatment should be
administered. Patients being discharged as early as possible
will also reduce infection frequency. We conclude that
TMPeSMX is anappropriate choice for Smaltophilia infection,
and that this can be safely used in neonates. Steno-
trophomonas maltophilia should be considered as a possible
agent in neonates with high Stenotrophomonas infection risk
factors. Early diagnosis and the commencement of appro-
priate antibiotics reduce mortality.References
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